摘要
目的:探讨口服普萘洛尔治疗婴幼儿增生期血管瘤的作用机制及临床疗效。方法:对42例增生期血管瘤患儿,给予普萘洛尔0.5~1.5mg/(kg·d)连续服用,服药3~8个月。采用ELISA法检测患儿治疗前、治疗4周、治疗8周时血清血管内皮生长因子(VEGF)的水平,并观察临床疗效及不良反应。结果:①42例增生期血管瘤患儿I级疗效有1例,Ⅱ级疗效2例,Ⅲ级疗效23例,Ⅳ级疗效16例,有效率(优加好)为92.9%。②42例增生期血管瘤在普萘洛尔治疗4周、8周时血清VEGF水平呈下降趋势,且治疗4周时低于治疗前(P〈0.05),治疗8周时低于治疗4周时(P〈0.05);治疗4周后血清VGEF下降水平与疗效等级具有正相关性(rs=0.705,P〈0.05),治疗8周后血清VGEF下降水平与疗效等级亦具有正相关性(rs=0.821,P〈0.001)。结论:普萘洛尔治疗婴幼儿增生期血管瘤疗效显著,不良反应轻微,其机制可能与下调增生期血管瘤患儿血清VEGF水平相关。
Objective: To explore the mechanism and clinical efficacy of propranolol for the treatment of infant proliferating hemangiomas by assessing the changes of serum vascular endothelial growth factor (VEGF). Methods: From December 2011 to March 2013, 42 infants with proliferating hemangiomas were treated with oral propranolol at a dose of 0.5-1.5 mg/(kg·d) for 3 to 8 months. Enzyme-linked immunosorbent assay (ELISA) was used to determine surum VEGF levels before, at 4 and 8 weeks after treatment. The clinical efficacy and adverse reactions were also observed. Results: (1)Of 42 cases, 1 case was scale, 2 cases were scale Ⅱ, 23 cases were scale Ⅲ and 16 cases were scale Ⅵ. The total effective rate was 92.9%. The serum VEGF levels gradually decreased during the treatment. The serum VEGF level was significantly lower after 4-week treatment (P〈 0.05). The level of serum VEGF after 8-week treatment also was significantly lower than that after 4-week treatment(P〈0.05). Following 4-and 8-week treatments, the decreased levels of serum VEGF were positively correlated with the grade of efficacy (rs=0.705, 0.821, P〈0.05, P〈0.001). Conclusion: Propranolol is safe and effective for the infant proliferating hemangiomas with mild adverse reactions. The mechanism may be associated with the down-regulation of serum VEGF.
出处
《临床皮肤科杂志》
CAS
CSCD
北大核心
2014年第11期682-684,共3页
Journal of Clinical Dermatology
关键词
普萘洛尔
增生期血管瘤
血管内皮生长因子
婴幼儿
propranolol
proliferating hemangiomas
vascular endothelial growth factor
infant